Clinical Data BMS brings the buzz around late-stage readouts amid a so-so Q1 Pharmaceutical TechnologyBMS is awaiting Phase III readouts from potential Eliquis successor, milvexian and schizophrenia med, Cobenfy, expected later this year.Read full story pharminent May 1, 2026 (Last updated: May 1, 2026) Pharmaceutical Technology BMS is awaiting Phase III readouts from potential Eliquis successor, milvexian and schizophrenia med, Cobenfy, expected later this year. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Where Gross-to-net Pressure Actually Lives After LaunchNext: Eli Lilly lifts 2026 revenue guidance as Q1 marks dominant opening Related Stories Clinical Data Boehringer advances duo for aggressive cancers into phase 3 pharminent June 22, 2026 Clinical Data Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short pharminent June 17, 2026 Clinical Data EHA26: BMS touts positive multiple myeloma data for two pipeline candidates pharminent June 17, 2026
